血浆微泡乳腺癌耐药蛋白mRNA水平对乳腺癌化疗疗效的预测价值分析

Predictive Value of Plasma Microbubble Breast Cancer Resistance Protein mRNALevel for Chemotherapy Efficacy of Breast Cancer

目的:探究乳腺癌病患化疗效果与血浆微泡乳腺癌耐药蛋白mRNA水平之间关系。方法:选择2019年5月~2020年5月在某院开展新辅助化疗的42例乳腺癌病患为实验组,另选择同时期进行健康体检的42例女性为对照组,分别对每组血浆微泡乳腺癌耐药蛋白mRNA水平进行检测统计,分析血浆微泡乳腺癌耐药蛋白水平对化疗疗效的预测价值。结果:实验组血浆微泡乳腺癌耐药蛋白mRNA相对含量是(256.31±32.18),高于对照组的(100.03±14.69),两组比较存在显著差异(P<0.05);42例乳腺癌病患开展新辅助化疗后,1例(2.38%)为PD,7例(16.67%)为SD,27例(64.29%)为PR,7例(16.67%)为CR,化疗总有效率是80.96%;化疗前血浆微泡乳腺癌耐药蛋白表达阴性以及(+)共19例,表达(++)者有13例、表达(+++)者有10例,阳性表达率是54.76%,在实施化疗后,PR组有9例转变为阳性表达,1例转为阴性,SD组有2例转为阳性表达;CR+PR组化疗前血浆微泡乳腺癌耐药蛋白阳性表达率是47.06%,SD+PR组化疗前血浆微泡乳腺癌耐药蛋白阳性表达率是87.50%,化疗前两组血浆微泡乳腺癌耐药蛋白阳性表达率、病理反应以及淋巴结转移方面比较存在明显差异(P<0.05);化疗后,SD+PR组血浆微泡中BCRPmRNA相对含量明显低于CR+PR组患者,差异有统计学意义(P<0.05)。结论:对于乳腺癌病患而言,其血浆微泡乳腺癌耐药蛋白mRNA水平在化疗前后有一定改变,其表达水平同化疗临床疗效、临床病理指标相关,因此可将其作为预测化学药物疗效的重要指标。

Objective:To explore the relationship between the effect of chemotherapy and the mRNA level of plasma microbubble breast cancer resistance protein in patients with breast cancer.Methods:42 patients with breast cancer who received neoadjuvant chemotherapy in a hospital from May 2019 to may 2020 were selected as the experimental group,and 42 women who received physical examination in a hospital during the same period were selected as the control group.The mRNA levels of plasma microbubble breast cancer resistance protein in each group were detected and statistically analyzed,and the predictive value of the mRNA level of plasma microbubble breast cancer resistance protein on chemotherapy efficacy was analyzed.Results:The relative content of MDRP mRNA in experimental group was(256.31±32.18),which was higher than that in control group(100.03±14.69).There was significant difference between the two groups(P<0.05).After neoadjuvant chemotherapy,1 case(2.38%)was PD,7 cases(16.67%)were SD,27 cases(64.29%)were PR and 7 cases(16.67%)were CR.The total effective rate of chemotherapy was 80.96%.Before chemotherapy,there were 19 cases with negative and(+)expression of MDRP in plasma.There were 13 cases with(++)expression and 10 cases with(+++)expression.The positive expression rate was 54.76%.After chemotherapy,9 cases in PR group were converted to positive,1 case was converted to negative,and 2 cases in SD group were converted to positive.The positive expression rate of MDRP in CR+PR group was 47.06%,and that in SD+PR group was 87.50%.Before chemotherapy,there was significant difference in the positive expression rate,pathological reaction and lymph node metastasis between the two groups(P<0.05).After chemotherapy,the relative content of BCRP mRNA in plasma microbubbles of SD+PR group was significantly lower than that of Cr+PR group(P<0.05).Conclusion:For patients with breast cancer,the expression level of MDRP mRNA in plasma has a certain change before and after chemotherapy.The expression level of MDRP mRNA is related to clinical efficacy and clinicopathological indexes.Therefore,it can be used as an important index to predict the efficacy of chemical drugs.